119 related articles for article (PubMed ID: 26084553)
1. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.
Su X; Song H; Niu F; Yang K; Kou G; Wang X; Chen H; Li W; Guo S; Li J; Li B; Feng SS; Jiang J; Yin C; Gao J
Nanomedicine (Lond); 2015; 10(13):2033-50. PubMed ID: 26084553
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
3. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
4. Bioactive lipids-based pH sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia.
Wang Y; Ding Y; Liu Z; Liu X; Chen L; Yan W
Pharm Res; 2013 Nov; 30(11):2902-16. PubMed ID: 23793993
[TBL] [Abstract][Full Text] [Related]
5. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells.
Uchida Y; Itoh M; Taguchi Y; Yamaoka S; Umehara H; Ichikawa S; Hirabayashi Y; Holleran WM; Okazaki T
Cancer Res; 2004 Sep; 64(17):6271-9. PubMed ID: 15342415
[TBL] [Abstract][Full Text] [Related]
6. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
7. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
8. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro.
Li F; Fan J; Wu Z; Liu RY; Guo L; Dong Z; Wang Z
Pharm Biol; 2013 Sep; 51(9):1196-203. PubMed ID: 23777360
[TBL] [Abstract][Full Text] [Related]
9. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS
Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance.
Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J
J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857
[TBL] [Abstract][Full Text] [Related]
11. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
12. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
15. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
Wang H; Li F; Du C; Wang H; Mahato RI; Huang Y
Mol Pharm; 2014 Aug; 11(8):2600-11. PubMed ID: 24405470
[TBL] [Abstract][Full Text] [Related]
17. Ceramide glycosylation potentiates cellular multidrug resistance.
Liu YY; Han TY; Giuliano AE; Cabot MC
FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
[TBL] [Abstract][Full Text] [Related]
18. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
